Syndecan 1 may slow the progression of subclinical atherosclerosis in patients with ankylosing spondylitis.

Pinar Diydem Yilmaz Cengiz Kadiyoran Mevlut Hakan GoktepeYasemin AkkubakAbdullah IcliAdem Kucuk

Published in: Clinical and experimental hypertension (New York, N.Y. : 1993) (2022)

S1 level may rise in AS patients to suppress the inverse effects of proinflammatory cytokines and inflammation. A negative relationship between the cIMT values of AS patients and S1 level may reveal that S1 has a protective effect on the development of atherosclerosis in AS patients, independent of disease activity.

Keyphrases

end stage renal disease
ankylosing spondylitis
disease activity
ejection fraction
chronic kidney disease
newly diagnosed
rheumatoid arthritis
peritoneal dialysis
systemic lupus erythematosus
prognostic factors
cardiovascular disease
oxidative stress
type diabetes
gene expression
patient reported outcomes